Axsome Therapeutics, Inc

Day range

$143.90 – $154.74

Open

$154.66

Prev close

$156.07

Volume

1.58M

Market cap

$8.18B

Shares out

52.38M

P/E

—

P/S

10.53

P/B

98.14

P/FCF

—

ROE

-230.1%

ROA

-25.2%

Debt/Equity

2.36

Div yield

0.00%

As of Oct 22, 2026

• Investor communicationsAug 10, 2026

  On August 10, 2026, the Company updated its corporate presentation and posted such corporate presentation to the Company's website. The updated corporate presentation is filed as Exhibit 99.2 hereto and incorporated by reference herein.

• Business developmentsJul 15, 2026

  the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy.

• Executive leadershipJun 9, 2026

  The Compensation Committee of the Board of Directors of Axsome Therapeutics, Inc. approved the adoption of the Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan (the 'Severance Plan'), effective on June 5, 2026, which provides for severance benefits to certain key employees, including the Company's named executive officers, upon certain types of qualifying termination events.

• Material agreementsJun 3, 2026

  On June 3, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release entitled "Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation."

• Investor communicationsMay 4, 2026

  On May 4, 2026, the Company updated its corporate presentation and posted such corporate presentation to the Company's website. The updated corporate presentation is filed as Exhibit 99.2 hereto and incorporated by reference herein.

• JAZZJazz Pharmaceuticals, Inc.-0.30%

Days to cover

4.4

Short interest

3.31M

Avg volume

758.36K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)
  positiveThe Motley Fool· Oct 23, 2026
• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
  positiveZacks Investment Research· Oct 21, 2026
• Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
  positiveGlobeNewswire Inc.· Oct 19, 2026
• 2 Under-the-Radar Stocks to Buy and Hold
  positiveThe Motley Fool· Oct 16, 2026